In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Sartan Medicinal Products: EMA’s Assesment Report defines Nitrosamine Limits and Reporting Deadlines

Sartan Medicinal Products: EMA’s Assesment Report defines Nitrosamine Limits and Reporting Deadlines

by In2Pharma | May 6, 2021 | News

Europe In a final assessment report, the EMA has published important information for marketing authorisation holders of angiotensin II receptor antagonists (sartans) regarding nitrosamine contamination limits and deadlines for risk mitigation measures. On 2 April...

Recent Posts

  • Update Belgian FAQ on nutrition and health claims
  • Simplification of disclaimers for promotional materials
  • REACH Microplastics Restriction: What You Need to Know – and Do – Today!
  • “Successive GMP certificate” applications
  • New contact form for questions on variations and renewals from 1 June 2025

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België